INGELHEIM, Germany & SINGAPORE--(BUSINESS WIRE)--Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback